Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 17 de 17
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Nature ; 532(7599): 334-9, 2016 Apr 21.
Article de Anglais | MEDLINE | ID: mdl-27049939

RÉSUMÉ

The serotonin transporter (SERT) terminates serotonergic signalling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons. SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signalling. Here we report X-ray crystallographic structures of human SERT at 3.15 Å resolution bound to the antidepressants (S)-citalopram or paroxetine. Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helices 1, 3, 6, 8 and 10, directly blocking serotonin binding. We further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helices 1, 6, 10 and 11. Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand. These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.


Sujet(s)
Transporteurs de la sérotonine/composition chimique , Transporteurs de la sérotonine/métabolisme , Régulation allostérique/effets des médicaments et des substances chimiques , Site allostérique/effets des médicaments et des substances chimiques , Antidépresseurs/composition chimique , Antidépresseurs/métabolisme , Antidépresseurs/pharmacologie , Citalopram/composition chimique , Citalopram/métabolisme , Citalopram/pharmacologie , Cristallographie aux rayons X , Transporteurs de la dopamine/composition chimique , Conception de médicament , Espace extracellulaire/métabolisme , Humains , Fragments Fab d'immunoglobuline/immunologie , Espace intracellulaire/métabolisme , Ions/composition chimique , Ions/métabolisme , Ligands , Modèles moléculaires , Paroxétine/composition chimique , Paroxétine/métabolisme , Paroxétine/pharmacologie , Liaison aux protéines/effets des médicaments et des substances chimiques , Conformation des protéines/effets des médicaments et des substances chimiques , Stabilité protéique , Sérotonine/métabolisme , Transporteurs de la sérotonine/immunologie , Relation structure-activité
2.
Usp Fiziol Nauk ; 45(4): 69-88, 2014.
Article de Russe | MEDLINE | ID: mdl-25729845

RÉSUMÉ

The paper presents evidence on the important contribution of the peripheral serotonin system in the process of immunomodulation. The main components of the system - serotonin, receptors and serotonin transporter - are described. Possible mechanisms of serotonin regulation of activity of immune cells - lymphocytes, macrophages and dendritic cells - are reviewed.


Sujet(s)
Régulation de l'expression des gènes/immunologie , Système immunitaire/physiologie , Récepteurs sérotoninergiques/immunologie , Transporteurs de la sérotonine/immunologie , Sérotonine/immunologie , Animaux , Cytokines/génétique , Cytokines/immunologie , Cellules dendritiques/immunologie , Ulcère duodénal/immunologie , Ulcère duodénal/physiopathologie , Humains , Système immunitaire/physiopathologie , Immunomodulation , Lymphocytes/immunologie , Macrophages/immunologie , Récepteurs sérotoninergiques/génétique , Sérotonine/génétique , Transporteurs de la sérotonine/génétique , Transduction du signal , Ulcère gastrique/immunologie , Ulcère gastrique/physiopathologie , Transmission synaptique
3.
Arch Dermatol Res ; 306(2): 181-8, 2014 Mar.
Article de Anglais | MEDLINE | ID: mdl-23989888

RÉSUMÉ

The immunopathogenesis of chronic non-healing Old World cutaneous leishmaniasis is challenging. There is a bidirectional communication between the nervous and immune systems, serotonin being an important mediator in this respect. Our aim was to study the role of the serotonin transporter protein (SERT) and its relation to T cell-related immune responses in lupoid leishmaniasis. Paraffin-embedded skin biopsies of 12 cases of lupoid and 12 cases of usual types of cutaneous leishmaniasis were investigated using immunohistochemistry regarding expression of SERT, Th1, Th2, Th17 and T regulatory cell (Treg) markers. SERT as well as Tregs and interleukin (IL)-17 positive cells were more prevalent while IL-5 (Th2) and interferon (IFN)-γ (Th1) expressing cells were less numerous in the lupoid tissue compared to those from the usual type of leishmaniasis. The majority of the SERT(+) cells were also tryptase(+) (mast cells). There was a positive correlation between a higher number of SERT(+) and IL-17(+) cells in the lupoid type, while lower numbers of SERT(+) cells were significantly related to lower percentages of CD25(+) cells in the usual type of leishmaniasis. These results might indicate a role for SERT, Th17 and Tregs in the pathogenesis of lupoid leishmaniasis.


Sujet(s)
Mastocytes/immunologie , Transporteurs de la sérotonine/métabolisme , Peau/immunologie , Lymphocytes T régulateurs/immunologie , Cellules Th17/immunologie , Adolescent , Adulte , Numération cellulaire , Enfant , Maladie chronique , Cytokines/métabolisme , Femelle , Humains , Immunité cellulaire , Immunohistochimie , Sous-unité alpha du récepteur à l'interleukine-2/métabolisme , Leishmaniose cutanée/immunologie , Mâle , Adulte d'âge moyen , Neuro-immunomodulation , Récidive , Transporteurs de la sérotonine/immunologie , Lymphocytes auxiliaires Th1/immunologie , Lymphocytes auxiliaires Th2/immunologie , Jeune adulte
4.
Mol Med Rep ; 9(1): 180-4, 2014 Jan.
Article de Anglais | MEDLINE | ID: mdl-24213511

RÉSUMÉ

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, which represents an economic burden to society and considerably reduces the quality of life of patients. In a previous study, the density of serotonin cells in the ileum of IBS patients was lower compared with control subjects. The present study aimed to further investigate the immunoreactivity intensity of serotonin and serotonin­selective reuptake transporter (SERT) in the ileum of IBS patients. A total of 98 patients (77 females and 21 males; mean age, 35 years; range, 18­66 years), which fulfilled Rome III Criteria for IBS, were included in the study. This cohort included 35 patients with diarrhoea­predominant (IBS­D), 31 patients with mixed diarrhoea and constipation (M­IBS) and 32 patients with constipation­predominant (IBS­C) symptoms. A total of 27 subjects were included as controls (16 females and 11 males; mean age, 52 years; range, 20­69 years). Ileal biopsy specimens were immunostained using the avidin­biotin (ABC) complex method for serotonin and SERT. The immunoreactivity intensity was quantified by computerised image analysis using Olympus cellSens imaging software. No statistical difference of serotonin immunoreactivity intensity was identified in multiple comparisons between controls, IBS­total, IBS­D, IBS­M and IBS­C. The SERT immunoreactivity intensity was significantly increased in IBS patients as compared with controls, regardless of the subtype. It was concluded that the increase in ileal epithelial content of SERT increases the intracellular uptake of serotonin and its degradation in the gut epithelial cells and consequently decreases the availability of serotonin within the gut mucosa. The low availability of serotonin at its receptors occurred in all IBS subtypes. This may indicate that this abnormality is associated with a common symptom in all IBS subtypes, namely abdominal pain/discomfort. Serotonin acts upon sensory neurons in the submucosal and myenteric ganglia, as well as in the spinal cord, which is in agreement with this hypothesis.


Sujet(s)
Iléum/métabolisme , Syndrome du côlon irritable/anatomopathologie , Transporteurs de la sérotonine/immunologie , Sérotonine/immunologie , Adolescent , Adulte , Sujet âgé , Coloscopie , Femelle , Humains , Immunohistochimie , Syndrome du côlon irritable/métabolisme , Mâle , Adulte d'âge moyen , Sérotonine/métabolisme , Transporteurs de la sérotonine/métabolisme , Jeune adulte
5.
J Neuroinflammation ; 10: 116, 2013 Sep 19.
Article de Anglais | MEDLINE | ID: mdl-24050835

RÉSUMÉ

BACKGROUND: Growing evidence suggests that alterations of the inflammatory/immune system contribute to the pathogenesis of depression. Indeed, depressed patients exhibit increased levels of inflammatory markers in both the periphery and the brain, and high comorbidity exists between major depression and diseases associated with inflammatory alterations. In order to characterize the link between depression and inflammation, we aimed to investigate whether an altered inflammatory system is present in a genetic model of vulnerability for depression, namely rats with partial or total deletion of the serotonin transporter (SERT) gene. METHODS: Wild-type, heterozygous and homozygous SERT rats were analyzed under basal condition or following a challenge with an acute injection of lipopolysaccharide (LPS) and killed 24 h or 5 days later. RESULTS: We found that SERT mutant rats show altered cytokine expression in the dorsal and ventral hippocampus at basal conditions, and they also display an exacerbated cytokine response to the LPS challenge. Moreover, mutant rats exhibit differences in the expression of markers for microglia activation. CONCLUSION: Based on these data, we suggest that basal or functional alterations of immune/inflammatory systems might contribute to the phenotype of SERT rats and to their heightened susceptibility to depressive-like behavior.


Sujet(s)
Dépression/immunologie , Hippocampe/immunologie , Inflammation/immunologie , Neuro-immunomodulation/immunologie , Transporteurs de la sérotonine/immunologie , Animaux , Cytokines/biosynthèse , Dépression/génétique , Dépression/métabolisme , Modèles animaux de maladie humaine , Hippocampe/métabolisme , Inflammation/induit chimiquement , Inflammation/génétique , Lipopolysaccharides/toxicité , Neuro-immunomodulation/génétique , Rats , Souches mutantes de rat , Réaction de polymérisation en chaine en temps réel , Transporteurs de la sérotonine/génétique
6.
Ross Fiziol Zh Im I M Sechenova ; 99(1): 17-32, 2013 Jan.
Article de Russe | MEDLINE | ID: mdl-23659053

RÉSUMÉ

Now that the neurotransmitter serotonin modulates the immune system cells, and its main sources for antigenpresenting cells and lymphocytes are enterochromaffin cells of the gut, peripheral nerves, platelets and mast cells in case of inflammation. Immune cells uptake serotonin because they express receptors for this monoamine and intracellular serotonin transporters. The dendritic cells have a mechanism to transfer serotonin to T lymphocytes during antigen presentation. The macrophages and T cells have the ability to serotonin synthesis. Serotonin can influence mobility and proliferation of lymphocytes, phagocytosis, cytolytic properties, synthesis of chemokines and cytokines. Diversity of immunomodulating effects of serotonin is determined by heterogeneity of serotoninergic receptors. Immunomodulating action of serotonin is evidence of the close relationship between nervous and immune systems.


Sujet(s)
Cellules dendritiques/métabolisme , Récepteurs sérotoninergiques/métabolisme , Transporteurs de la sérotonine/métabolisme , Sérotonine/métabolisme , Lymphocytes T/métabolisme , Animaux , Présentation d'antigène , Cytokines/immunologie , Cellules dendritiques/immunologie , Cellules entérochromaffines/immunologie , Cellules entérochromaffines/métabolisme , Humains , Immunité innée , Immunomodulation , Macrophages/immunologie , Macrophages/métabolisme , Mastocytes/immunologie , Mastocytes/métabolisme , Récepteurs sérotoninergiques/classification , Récepteurs sérotoninergiques/immunologie , Sérotonine/immunologie , Sérotonine/pharmacologie , Transporteurs de la sérotonine/immunologie , Transduction du signal , Lymphocytes T/immunologie
7.
Genes Brain Behav ; 12(3): 353-60, 2013 Apr.
Article de Anglais | MEDLINE | ID: mdl-23331374

RÉSUMÉ

Individual variation in serotonergic function is associated with reactivity, risk for affective disorders, as well as an altered response to disease. Our study used a nonhuman primate model to further investigate whether a functional polymorphism in the promoter region for the serotonin transporter gene helps to explain differences in proinflammatory responses. Homology between the human and rhesus monkey polymorphisms provided the opportunity to determine how this genetic variation influences the relationship between a psychosocial stressor and immune responsiveness. Leukocyte numbers in blood and interleukin-6 (IL-6) responses are sensitive to stressful challenges and are indicative of immune status. The neutrophil-to-lymphocyte ratio and cellular IL-6 responses to in vitro lipopolysaccharide stimulation were assessed in 27 juvenile male rhesus monkeys while housed in stable social groups (NLL = 16, NS = 11) and also in 18 animals after relocation to novel housing (NLL = 13, NS = 5). Short allele monkeys had significantly higher neutrophil-to-lymphocyte ratios than homozygous Long allele carriers at baseline [t(25) = 2.18, P = 0.02], indicative of an aroused state even in the absence of disturbance. In addition, following the housing manipulation, IL-6 responses were more inhibited in short allele carriers (F1,16 = 8.59, P = 0.01). The findings confirm that the serotonin transporter gene-linked polymorphism is a distinctive marker of reactivity and inflammatory bias, perhaps in a more consistent manner in monkeys than found in many human studies.


Sujet(s)
Génotype , Polymorphisme génétique/immunologie , Transporteurs de la sérotonine/génétique , Allèles , Animaux , Éveil , Hétérozygote , Homozygote , Interleukine-6/sang , Interleukine-6/immunologie , Leucocytes/immunologie , Lipopolysaccharides/immunologie , Macaca mulatta , Mâle , Régions promotrices (génétique) , Transporteurs de la sérotonine/immunologie , Stress psychologique/génétique , Stress psychologique/immunologie
8.
Cell Death Dis ; 2: e210, 2011 Sep 15.
Article de Anglais | MEDLINE | ID: mdl-21918544

RÉSUMÉ

Alzheimer's disease (AD) is a neurodegenerative pathology that deteriorates mnesic functions and associated brain regions including the hippocampus. Serotonin (5-HT) has an important role in cognition. We recently demonstrated an increase in 5-HT transporter (SERT) fibre density in the hippocampal CA1 in an AD triple transgenic mouse model (3xTg-AD). Here, we analyse the ultrastructural localisation, distribution and numerical density (N(v)) of hippocampal SERT axons (SERT-Ax) and terminals (SERT-Te) and their relationship with SERT fibre sprouting and altered synaptic N(v) in 3xTg-AD compared with non-transgenic control mice. 3xTg-AD animals showed a significant increase in SERT-Te N(v) in CA1 at both, 3 (95%) and 18 months of age (144%), being restricted to the CA1 stratum moleculare (S. Mol; 227% at 3 and 180% at 18 months). 3xTg-AD animals also exhibit reduced N(v) of perforated axospinous synapses (PS) in CA1 S. Mol (56% at 3 and 52% at 18 months). No changes were observed in the N(v) of symmetric and asymmetrical synapses or SERT-Ax. Our results suggest that concomitant SERT-Te N(v) increase and PS reduction in 3xTg-AD mice may act as a compensatory mechanism maintaining synaptic efficacy as a response to the AD cognitive impairment.


Sujet(s)
Maladie d'Alzheimer/métabolisme , Région CA1 de l'hippocampe/métabolisme , Région CA1 de l'hippocampe/ultrastructure , Transporteurs de la sérotonine/métabolisme , Maladie d'Alzheimer/génétique , Maladie d'Alzheimer/anatomopathologie , Amyloïde/métabolisme , Animaux , Modèles animaux de maladie humaine , Souris , Souris transgéniques , Neurofibres/ultrastructure , Transporteurs de la sérotonine/immunologie
9.
Neuropharmacology ; 60(7-8): 1347-54, 2011 Jun.
Article de Anglais | MEDLINE | ID: mdl-21329710

RÉSUMÉ

Imaging studies of serotonin transporter binding or tryptophan retention in autistic patients suggest that the brain serotonin system is decreased. However, treatment with drugs which increase serotonin (5-HT) levels, specific serotonin reuptake inhibitors (SSRIs), commonly produce a worsening of the symptoms. In this study we examined 5-HT axons that were immunoreactive to a serotonin transporter (5-HTT) antibody in a number of postmortem brains from autistic patients and controls with no known diagnosis who ranged in age from 2 to 29 years. Fine, highly branched, and thick straight fibers were found in forebrain pathways (e.g. medial forebrain bundle, stria terminalis and ansa lenticularis). Many immunoreactive varicose fine fibers were seen in target areas (e.g. globus pallidus, amygdala and temporal cortex). Morphometric analysis of the stained axons at all ages studied indicated that the number of serotonin axons was increased in both pathways and terminal regions in cortex from autism donors. Our findings provide morphological evidence to warrant caution when using serotonin enhancing drugs (e.g. SSRIs and receptor agonist) to treat autistic children. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.


Sujet(s)
Trouble autistique/métabolisme , Axones/métabolisme , Encéphale/métabolisme , Transporteurs de la sérotonine/métabolisme , Sérotonine/métabolisme , Adolescent , Adulte , Autopsie , Encéphale/anatomopathologie , Enfant , Enfant d'âge préscolaire , Femelle , Globus pallidus/physiologie , Humains , Mâle , Faisceau télencéphalique médial/physiologie , Neurofibres/physiologie , Prosencéphale/physiologie , Sérotonine/immunologie , Transporteurs de la sérotonine/immunologie , Subthalamus/physiologie , Lobe temporal/physiologie , Jeune adulte
10.
Horm Behav ; 56(4): 391-8, 2009 Oct.
Article de Anglais | MEDLINE | ID: mdl-19632235

RÉSUMÉ

Early life experiences have been shown to adjust cognitive abilities, stress reactivity, fear responses and immune activity in adult mammals of many species. However, whereas severe stressors have been generally associated with the emergence of hypothalamic pituitary adreno-cortical (HPA)-mediated pathology, mild neonatal stressful experiences have been traditionally associated with 'positive' effects or resilience. External stressors stimulate the HPA axis to induce a corticosterone secretion in mouse dams, which, in turn is directly transmitted to the progeny through lactation. Such corticosteroid transfer may offer a unitary mechanism whereby early low corticosterone exposure may favor resilience in the offspring and high corticosterone increase vulnerability to pathology. In this study we further investigated this hypothesis by evaluating the long-term effects of a neonatal exposure to low (33 mg/l) and high (100 mg/l) doses of corticosterone during the first 10 days of life in outbred CD-1 mice through supplementation in the maternal drinking water. Offspring attentional set-shifting abilities, central neurotrophic regulation and levels of natural auto-antibodies (na-Abs) directed to serotonin (SERT) and dopamine (DAT) transporters were assessed in adulthood. While low levels of neonatal corticosterone improved adult cognitive abilities and increased na-Abs levels directed to SERT, high doses of neonatal corticosterone reduced hippocampal BDNF levels and na-Abs directed to DAT. These findings confirm and extend our previous findings, supporting the view that both adaptive plasticity and pathological outcomes in adulthood may depend on circulating neonatal corticosterone levels and that these effects follow a U-shaped profile.


Sujet(s)
Encéphale/effets des médicaments et des substances chimiques , Cognition/effets des médicaments et des substances chimiques , Corticostérone/pharmacologie , Stress psychologique/induit chimiquement , Animaux , Animaux nouveau-nés , Autoanticorps/sang , Autoanticorps/métabolisme , Encéphale/croissance et développement , Encéphale/physiopathologie , Facteur neurotrophique dérivé du cerveau/métabolisme , Cognition/physiologie , Corticostérone/administration et posologie , Corticostérone/sang , Transporteurs de la dopamine/immunologie , Relation dose-effet des médicaments , Femelle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/croissance et développement , Hippocampe/physiopathologie , Mâle , Souris , Lignées consanguines de souris , Tests neuropsychologiques , Transporteurs de la sérotonine/immunologie , Stress psychologique/physiopathologie , Facteurs temps
11.
Innate Immun ; 15(4): 243-50, 2009 Aug.
Article de Anglais | MEDLINE | ID: mdl-19587001

RÉSUMÉ

Intestinal serotoninergic activity and serotonin transporter (SERT) function have been shown to be altered in intestinal inflammatory diseases. Serotonin (5-HT) plays a critical role in the regulation of gastrointestinal physiology. Activity of 5-HT depends on its extracellular availability, partly modulated by SERT that transports 5-HT into the cell. Lipopolysaccharide (LPS) is a component of Gram-negative bacteria outer membrane, which acts as a potent activator of the inflammatory system in the intestine. The aim of this work was to determine, in the enterocyte-like cell line Caco-2, whether LPS treatment affects serotoninergic activity by acting on SERT. The results demonstrate that LPS treatment diminishes SERT activity in a dose- and period-dependent way. The kinetic study shows that V(max) was significantly reduced after treatment with LPS. The LPS effect on 5-HT uptake was, in part, mediated by protein kinase C (PKC) activation. The molecular expression of SERT revealed that LPS treatment did not affect the mRNA level or the SERT protein content in cell homogenate. The level of SERT protein, however, was reduced on brush border membrane. The LPS effect might be due to an alteration of the intracellular traffic of SERT which may, in part, be mediated by PKC activity.


Sujet(s)
Entérocytes/métabolisme , Gastroentérite/physiopathologie , Muqueuse intestinale/métabolisme , Lipopolysaccharides/métabolisme , Transporteurs de la sérotonine/métabolisme , Cellules Caco-2 , Entérocytes/immunologie , Entérocytes/ultrastructure , Activation enzymatique/immunologie , Gastroentérite/immunologie , Gastroentérite/anatomopathologie , Humains , Muqueuse intestinale/immunologie , Muqueuse intestinale/anatomopathologie , Lipopolysaccharides/immunologie , Microvillosités/métabolisme , Microvillosités/ultrastructure , Protéine kinase C/immunologie , Protéine kinase C/métabolisme , Transport des protéines , Sérotonine/immunologie , Sérotonine/métabolisme , Transporteurs de la sérotonine/immunologie
12.
Arch Dermatol Res ; 301(6): 449-57, 2009 Jul.
Article de Anglais | MEDLINE | ID: mdl-19263059

RÉSUMÉ

Since the symptoms of psoriasis may be changed by treatment with selective serotonin reuptake inhibitors (SSRIs), the expression of serotonin (5-HT) and its transporter protein (SERT) in the skin of patients with psoriasis were examined employing a biotinylated-streptavidine procedure. In biopsies of such skin staining for 5-HT was limited to platelets; the expression of SERT in the keratinocytes of involved regions was redistributed; the numbers of SERT-positive dendritic or round mononuclear cells in the epidermis of involved psoriatic skin were higher than in normal healthy control skin; and the dermis of the involved skin contained higher numbers of round inflammatory cells immunostained for SERT than either non-involved psoriatic skin or normal skin. Double-immunostaining indicated that the skin cells expressing SERT also expressed CD1a, CD3 or tryptase. In addition, SERT immunostaining was co localized with caspase-3, a key regulator of apoptosis, but not with TUNEL staining. The present findings indicate that SERT might play a role in regulating apoptosis in inflammatory cells associated with psoriasis, in which case this protein might constitute a valuable therapeutic target.


Sujet(s)
Derme/métabolisme , Épiderme/métabolisme , Psoriasis/anatomopathologie , Transporteurs de la sérotonine/métabolisme , Sérotonine/métabolisme , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Antigènes CD1 , Apoptose/immunologie , Plaquettes/immunologie , Plaquettes/métabolisme , Plaquettes/anatomopathologie , Antigènes CD3 , Caspase-3/immunologie , Caspase-3/métabolisme , Derme/immunologie , Derme/anatomopathologie , Épiderme/immunologie , Épiderme/anatomopathologie , Femelle , Humains , Immunohistochimie , Kératinocytes/immunologie , Kératinocytes/métabolisme , Kératinocytes/anatomopathologie , Cellules de Langerhans/immunologie , Cellules de Langerhans/métabolisme , Cellules de Langerhans/anatomopathologie , Mâle , Adulte d'âge moyen , Psoriasis/immunologie , Psoriasis/métabolisme , Sérotonine/immunologie , Transporteurs de la sérotonine/immunologie
13.
Int Immunopharmacol ; 9(4): 463-7, 2009 Apr.
Article de Anglais | MEDLINE | ID: mdl-19189865

RÉSUMÉ

Several lines of evidences indicate that antidepressants produce various immunomodulatory effects. Fluoxetine, an antidepressant and selective serotonin reuptake inhibitor, modulates immune cells in vitro. To explore the in vivo influence of fluoxetine on lymphocytes, male Sprague-Dawley rats were treated daily, 10 mg/kg, or with saline solution for 1, 2 and 3 weeks. The presence of serotonin transporter in CD3+, CD4+ and CD8+ subpopulations of T lymphocytes was determined by immunofluorescence. Serotonin transporter was also labeled with [(3)H]paroxetine, specific binding defined with imipramine. Plasma levels of pro-inflammatory interleukin 2 (IL-2), and anti-inflammatory interleukin 4 (IL-4), were measured by ELISA; and cAMP concentration by radioimmunoassay. Fluoxetine significantly increased the number of lymphocytes expressing serotonin transporter and elevated the binding of [(3)H]paroxetine. The percentage of CD4+ cells decreased, that of CD8+ increased, and CD3+ did not change. The ratio CD4+/CD8+ was significantly lowered. Fluoxetine administration elevated the levels of IL-4 at 1, 2 and 3 weeks; and of IL-2, at 2 and 3 weeks. IL-4/IL-2 ratio was significantly increased in fluoxetine group respecting the controls and was similar during the 3 weeks of treatment. Fluoxetine produced a significant decrease in cAMP concentrations in lymphocytes, probably by secondary activation of serotonin receptors. Treatment with fluoxetine modified immune parameters in plasma and lymphocytes of rats, which might be relevant for its systemic therapeutic action as an antidepressant.


Sujet(s)
Antidépresseurs de seconde génération/pharmacologie , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Lymphocytes T CD8+/effets des médicaments et des substances chimiques , Fluoxétine/pharmacologie , Facteurs immunologiques/pharmacologie , Inbiteurs sélectifs de la recapture de la sérotonine/pharmacologie , AMP/immunologie , AMP/métabolisme , Animaux , Lymphocytes T CD4+/immunologie , Lymphocytes T CD8+/immunologie , Interleukine-2/sang , Interleukine-4/sang , Mâle , Rats , Rat Sprague-Dawley , Transporteurs de la sérotonine/immunologie , Transporteurs de la sérotonine/métabolisme
14.
Arch Dermatol Res ; 301(6): 443-7, 2009 Jul.
Article de Anglais | MEDLINE | ID: mdl-18979110

RÉSUMÉ

Serotonin is a monoamine acting as a neuromediator in the central and peripheral nervous system. Recently, serotonin has also been shown to influence T- and B-cell function. The serotonin transporter is central in the regulation of the serotonergic system and widely expressed on cells of the immune system. A functional length polymorphism in the promoter of the serotonin transporter gene (5-HTTLPR) has been implicated in the genetic background of depression. Psoriasis is a complex disease with a polygenetic inheritance. In light of the role of T-cell mediated inflammation in psoriasis and the increased prevalence of depression in psoriatic patients, we analyzed the 5-HTTLPR polymorphism in 309 patients with psoriasis vulgaris and 315 healthy control individuals. No significant differences in genotype distribution and allele frequencies were found. There was also no difference in the score of the Hamilton Rating Scale for Depression in patients with psoriasis (n = 137) characterized by carriage of different 5-HTTLPR genotypes. These findings argue against a major contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility and the occurrence of depressive symptoms among psoriatic patients.


Sujet(s)
Psoriasis/génétique , Transporteurs de la sérotonine/génétique , Adulte , Études cas-témoins , Dépression , Évolution de la maladie , Femelle , Fréquence d'allèle , Prédisposition génétique à une maladie , Génotype , Humains , Mâle , Adulte d'âge moyen , Polymorphisme génétique , Psoriasis/immunologie , Psoriasis/physiopathologie , Psoriasis/psychologie , Transporteurs de la sérotonine/immunologie , Transporteurs de la sérotonine/métabolisme , Indice de gravité de la maladie
15.
Am J Physiol Gastrointest Liver Physiol ; 296(3): G685-95, 2009 Mar.
Article de Anglais | MEDLINE | ID: mdl-19095763

RÉSUMÉ

Serotonin (5-HT) regulates peristaltic and secretory reflexes in the gut. The serotonin reuptake transporter (SERT; SLC6A4), which inactivates 5-HT, is expressed in the intestinal mucosa and the enteric nervous system. Stool water content is increased and colonic motility is irregular in mice with a targeted deletion of SERT. We tested the hypotheses that 5-HT plays a role in regulating intestinal inflammation and that the potentiation of serotonergic signaling that results from SERT deletion is proinflammatory. Rectal installation of 2,4,6-trinitrobenzene sulfonic acid (TNBS) was used to induce an immune-mediated colitis, which was compared in SERT knockout mice and littermate controls. Intestinal myeloperoxidase and histamine levels were significantly increased, whereas the survival rate and state of health were significantly decreased in TNBS-treated mice that lacked SERT. Deletion of SERT thus increases the severity of TNBS colitis. These data suggest that 5-HT and its SERT-mediated termination play roles in intestinal immune/inflammatory responses in mice.


Sujet(s)
Colite/physiopathologie , Transporteurs de la sérotonine/génétique , Transporteurs de la sérotonine/immunologie , Sérotonine/métabolisme , Animaux , Colite/induit chimiquement , Colite/mortalité , Côlon/physiologie , Motilité gastrointestinale/immunologie , Histamine/métabolisme , Souris , Souris de lignée C57BL , Souris knockout , Myeloperoxidase/métabolisme , Rectum/physiologie , Transporteurs de la sérotonine/métabolisme , Acide 2,4,6-trinitro-benzènesulfonique/toxicité
16.
Clin Exp Pharmacol Physiol ; 34(8): 702-7, 2007 Aug.
Article de Anglais | MEDLINE | ID: mdl-17600544

RÉSUMÉ

1. Ketanserin may influence baroreflex function by blocking 5-HT(2A) receptors and/or alpha(1)-adrenoceptors through central and/or peripheral mechanisms. 2. In the present study, we tested the hypothesis that the baroreflex sensitivity (BRS)-enhancing effects of ketanserin are mediated by central 5-HT(2A) receptors in spontaneously hypertensive rats (SHR). 3. Using a conjugate of a monoclonal antibody to the serotonin reuptake transporter (SERT) and the toxin saporin (anti-SERT-SAP), which specifically eliminates the neurons that express SERT, the effects of ketanserin (0.3 and 3.0 mg/kg, i.g.) on BRS, blood pressure (BP), heart period (HP) and blood pressure variability (BPV) were compared between conscious intact SHR and SHR pretreated with anti-SERT-SAP. 4. Immunochemistry showed that, 2 weeks after intracerebroventricular injection of the toxin, 5-HT expression was strikingly attenuated in the brain, whereas values of BRS, BPV and BP were similar to those in the sham group. In intact SHR, 0.3 mg/kg ketanserin significantly improved BRS (191% control) and reduced BPV without affecting BP; at 3.0 mg/kg, ketanserin significantly increased BRS (197% control) and decreased BPV and BP. In toxin-pretreated SHR, only the high dose of ketanserin improved BRS (132% control), neither of the ketanserin doses reduced BPV, but both significantly decreased BP. 5. We conclude that the BRS-enhancing effects of ketanserin are mediated largely by central 5-HT(2A) receptors, whereas the antihypertensive effect of ketanserin persists even after destruction of serotonergic neurons in the central nervous system.


Sujet(s)
Antihypertenseurs/pharmacologie , Baroréflexe/effets des médicaments et des substances chimiques , Encéphale/effets des médicaments et des substances chimiques , Hypertension artérielle/traitement médicamenteux , Kétansérine/pharmacologie , Antagonistes des récepteurs 5-HT2 de la sérotonine , Antisérotonines/pharmacologie , Animaux , Anticorps monoclonaux , Antihypertenseurs/usage thérapeutique , Pression sanguine/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Encéphale/anatomopathologie , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Rythme cardiaque/effets des médicaments et des substances chimiques , Hypertension artérielle/métabolisme , Hypertension artérielle/physiopathologie , Immunotoxines/toxicité , Kétansérine/usage thérapeutique , N-Glycosyl hydrolases/toxicité , Neurones/effets des médicaments et des substances chimiques , Neurones/métabolisme , Protéines végétales/toxicité , Rats , Rats de lignée SHR , Récepteur de la sérotonine de type 5-HT2A/métabolisme , Protéines inactivant les ribosomes de type 1 , Saporines , Sérotonine/métabolisme , Antisérotonines/usage thérapeutique , Transporteurs de la sérotonine/immunologie , Transporteurs de la sérotonine/métabolisme
17.
Blood ; 107(3): 1010-7, 2006 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-16223770

RÉSUMÉ

Adaptive immunity is triggered at the immune synapse, where peptide-major histocompatibility complexes and costimulatory molecules expressed by dendritic cells (DCs) are physically presented to T cells. Here we describe transmission of the inflammatory monoamine serotonin (5-hydroxytryptamine [5-HT]) between these cells. DCs take up 5-HT from the microenvironment and from activated T cells (that synthesize 5-HT) and this uptake is inhibited by the antidepressant, fluoxetine. Expression of 5-HT transporters (SERTs) is regulated by DC maturation, exposure to microbial stimuli, and physical interactions with T cells. Significantly, 5-HT sequestered by DCs is stored within LAMP-1+ vesicles and subsequently released via Ca2+-dependent exocytosis, which was confirmed by amperometric recordings. In turn, extracellular 5-HT can reduce T-cell levels of cAMP, a modulator of T-cell activation. Thus, through the uptake of 5-HT at sites of inflammation, and from activated T cells, DCs may shuttle 5-HT to naive T cells and thereby modulate T-cell proliferation and differentiation. These data constitute the first direct measurement of triggered exocytosis by DCs and reveal a new and rapid type of signaling that may be optimized by the intimate synaptic environment between DCs and T cells. Moreover, these results highlight an important role for 5-HT signaling in immune function and the potential consequences of commonly used drugs that target 5-HT uptake and release.


Sujet(s)
Cellules dendritiques/immunologie , Activation des lymphocytes/immunologie , Sérotonine/immunologie , Transduction du signal/immunologie , Lymphocytes T/immunologie , Animaux , Différenciation cellulaire/immunologie , Prolifération cellulaire , Cellules cultivées , Cellules dendritiques/cytologie , Exocytose/immunologie , Protéine de membrane-1 associée au lysosome/immunologie , Souris , Transporteurs de la sérotonine/immunologie , Membranes synaptiques/immunologie , Lymphocytes T/cytologie , Vésicules de transport/immunologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...